{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-25-002413","form_type":"8-K","ticker":"RFL","cik":"0001713863","company_name":"Rafael Holdings, Inc.","filed_at":"2025-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.561205+00:00","generated_at":"2026-05-24T05:03:11.445950+00:00","sec_items":["2.01","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Rafael Holdings completes merger with Cyclo Therapeutics after shareholder approvals","bullets":["Cyclo shareholders received 0.3525 shares of Rafael Class B common stock per share; Rafael issued approximately 7,132,228 shares.","Cyclo's Phase 3 TransportNPC trial for Niemann-Pick Type C1 is fully enrolled; 48-week interim analysis expected mid-2025.","Markus W. Sieger, former Cyclo Chairman, appointed to Rafael board as independent director.","Certain Cyclo warrants converted into Rafael warrants; new warrants to be publicly traded on NYSE American around March 31, 2025.","Cyclo common stock (CYTH) suspended from Nasdaq as of March 25, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-25-002413","json":"https://secwatch.observer/filing/0001013762-25-002413.json","markdown":"https://secwatch.observer/filing/0001013762-25-002413.md","text":"https://secwatch.observer/filing/0001013762-25-002413.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1713863/000101376225002413/0001013762-25-002413-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1713863/000101376225002413/ea0235617-8k_rafael.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-24T05:03:11.445950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"71b3934b19","claim":"Markus W. Sieger was appointed as Director at Rafael Holdings, Inc..","evidence_excerpt":"On March 25, 2025, effective as of the Effective Time, Markus W. Sieger, former Chairman of the Board of Cyclo, was appointed as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1713863/000101376225002413/0001013762-25-002413-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d88f477f4e4db9d9e348ff561b1d3166bd1fc49a","claim":"Rafael Holdings, Inc. completed an acquisition involving Cyclo Therapeutics, Inc. (closed 2025-03-25).","evidence_excerpt":"On March 25, 2025, Rafael Holdings, Inc., a Delaware corporation (“Rafael”), completed the previously announced business combination transaction with Cyclo Therapeutics, Inc., a Nevada corporation (“Cyclo”) contemplated by that certain Agreement and Plan of Merger, dated as of August 21, 2024","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1713863/000101376225002413/0001013762-25-002413-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Cyclo Therapeutics, Inc."},{"label":"Closing","value":"2025-03-25"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}